Press releaseBusiness Wire
United Therapeutics
UTHR · NASDAQ
$553.88+$10.73 (+1.98%)TodayMarket closed ·
Prev close $543.15
Latest news
- Press releaseBusiness Wire
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
- NewsRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)
- NewsNeeraj Jain
Liquidia Settles Bitter Fight With United Therapeutics
- Press releaseGlobe Newswire
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
- Press releaseBusiness Wire
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
- NewsHenry Khederian
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
- NewsAvi Kapoor
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- Press releasePRNewswire
HLS Therapeutics Announces Board of Directors Changes
- NewsMohd Haider
Why is Liquidia (LQDA) Stock Trending After Hours?
- Press releaseBusiness Wire
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
- NewsPiero Cingari
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
- Press releaseBusiness Wire
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
- Press releaseBusiness Wire
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
- Press releaseBusiness Wire
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
- Press releaseBusiness Wire
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
- Press releaseBusiness Wire
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
- Press releaseBusiness Wire
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
- Press releaseBusiness Wire
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
- Press releaseBusiness Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
- Press releaseBusiness Wire
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
- Press releaseBusiness Wire
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
- Press releaseBusiness Wire
BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program
- NewsVandana Singh
United Therapeutics Expands Immune Therapy Pipeline With Thymmune
- News
United Therapeutics Acquired Thymmune Therapeutics For $140M In Cash
- Press releaseBusiness Wire
United Therapeutics Corporation Acquires Thymmune Therapeutics
- NewsVandana Singh
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
- Press releaseBusiness Wire
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
- Press releaseBusiness Wire
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
- News
United Therapeutics Says New England Journal Of Medicine Publishes Full Results Of TETON-1 Study And Combined Analyses Of TETON-1, TETON-2 Studies, Evaluating Use Of Nebulized Tyvaso For Treatment Of IPF
- Press releaseBusiness Wire
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
- NewsAvi Kapoor
Baidu, Brady And 3 Stocks To Watch Heading Into Monday
- Press releaseBusiness Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
- Press releaseBusiness Wire
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
- Press releasePRNewswire
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease
- News
Earnings Scheduled For May 6, 2026
- News
Transcript: United Therapeutics Q1 2026 Earnings Conference Call
- News
MannKind Develops Dry Powder Inhalation Formulation Of Ralinepag, Known As Ralinepag DPI, For United Therapeutics
- News
United Therapeutics Q1 EPS $5.82 Misses $6.92 Estimate, Sales $781.500M Miss $796.921M Estimate
- Press releaseBusiness Wire
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
- News
P/E Ratio Insights for United Therapeutics
- News
A Look Into United Therapeutics Inc's Price Over Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.